Preferred Label : Allogeneic CRISPR-edited Anti-CD19 CAR T Cells PBLTT52CAR19;
NCIt synonyms : Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells PBLTT52CAR19; Allogeneic CRISPR-edited Anti-CD19 CAR T-cells PBLTT52CAR19;
NCIt definition : A preparation of allogeneic T-lymphocytes transduced with a lentiviral vector encoding
a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA)
CD19, with genetic modification of CD52 and T-cell receptor alpha constant (TRAC)
loci via clustered regularly interspaced short palindromic repeats (CRISPR), with
potential immunostimulating and antineoplastic activities. Upon administration, the
allogeneic CRISPR-edited anti-CD19 CAR T cells PBLTT52CAR19 recognize and bind to
CD19-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte
(CTL)-mediated killing of CD19-positive tumor cells. CD19 antigen is a B-cell specific
cell surface antigen expressed in all B-cell lineage malignancies. The editing of
the CD52 gene may make the modified donor T-cells resistant to the anti-CD52 monoclonal
antibody alemtuzumab, which is used during lymphodepletion. The editing of the TRAC
may eliminate TCR expression, which may abrogate the potential induction of graft-versus-host
disease (GvHD) by the donor T-cells, and may also result in uniform CAR expression
and enhanced T-cell potency.;
Molecule name : PBLTT52 CAR19; PBLTT52-CAR19;
NCI Metathesaurus CUI : CL1648136;
Origin ID : C178434;
UMLS CUI : C5555029;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
